# Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement

> **NCT03531294** · PHASE2 · COMPLETED · sponsor: **Greater Houston Retina Research** · enrollment: 40 (actual)

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **DRUG:** Aflibercept Injection

## Key facts

- **NCT ID:** NCT03531294
- **Lead sponsor:** Greater Houston Retina Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-23
- **Primary completion:** 2021-04-09
- **Final completion:** 2021-04-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-05-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03531294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03531294, "Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03531294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*